Superworth

Inhibrx Biosciences revenue INBX

Sales by quarter and over the last twelve months, from 2023.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
$0
−100% on a year earlier
Fiscal year 2025
n/a

Inhibrx Biosciences' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was $0, down 100% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025n/an/a
FY2024$200K−89%
FY2023$1.8Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$0−100%n/a
Q4 FY25$0−100%n/a
Q3 FY25$0n/an/a
Q2 FY25$1.3M+1200%n/a
Q4 FY24$100K−94%$200K
Q3 FY24$0−100%$1.7M
Q2 FY24$100K+233%$1.9M
Q1 FY24$0−100%$1.8M
Q4 FY23$1.6Mn/a$1.8M
Q3 FY23$119Kn/an/a
Q2 FY23$30Kn/an/a
Q1 FY23$17Kn/an/a

Against its peers

Companies in Biotechnology nearest Inhibrx Biosciences' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
INBXInhibrx Biosciencesn/m
MGTXMeiraGTx$397.5M
VCELVericel$306.3M+23% a year
ADMAAdma Biologics$512.3M+8% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
KRYSKrystal Biotech$440.5M+23% a year
RGENRepligen$785.1M+16% a year
TECHBIO-TECHNE$1.2B−0% a year
Peer median$440.5M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Inhibrx Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.